TEMODAR: profile and news

MD Anderson: Setting the Benchmark in Brain Tumor Treatment  May 14, 2006
The chemotherapy drug Temodar (temozolomide), first tested by MD Anderson researchers in recurrent glioblastoma and approved for use in those tumors last year ... - Medical News Today (press release),

Schering-Plough Reports Financial Results for First Quarter of ...  Apr 20, 2006
...said Hassan. He pointed to products posting higher sales in the 2006 first quarter, including REMICADE, NASONEX and TEMODAR. "Our ... - International News Service,

Update 1: Schering-Plough Quarterly Earnings Triple  Apr 20, 2006
...quarterly sales rose 7.7 percent, to $2.55 billion from $2.37 billion, as it also reported growth in sales of the brain tumor treatment Temodar and hepatitis C ... - Forbes

AANS: Vaccine Slows Glioblastoma In Phase II Trial  Apr 25, 2006
By contrast, she said, median survival is 14 months for patients with GBM who are treated with radiation and Temodar (temozolomide). ... - MedPage Today,

Cancer-drug makers weigh price limits  May 10, 2006
Fred Hassan, chief executive of Schering-Plough Corp., maker of Temodar, a drug for brain tumors, says the controversy over escalating cancer-drug prices is ... - Pittsburgh Post Gazette,

Schering-Plough 1Q profit triples  Apr 20, 2006
Sales rose to $2.55 billion from $2.37 billion, led by growth of its Remicade, Nasonex, Temodar and PEG-Intron prescription pharmaceuticals. ... - BusinessWeek

Could Schering-Plough Do More With More?  Apr 20, 2006
...this quarter. Remicade, Nasonex, and Temodar all posted 25% or better revenue growth, and PEG-Intron was up 16% as well. Speaking ... - Motley Fool

Fluorescence-Guided Surgery Improves Outcomes in Malignant Glioma  Apr 26, 2006
There is also evidence that completeness of surgery is necessary for maximum benefits of adjuvant therapies such as chemotherapy (Temodar®) and radiotherapy. ... - Cancer Consultants (press release),

Schering-Plough profits zoom  Apr 20, 2006
That will not change.". Schering-Plough said it saw substantial sales growth in many of its products, particularly Remicade, Nasonex, Temodar, and Peg-Intron. ... - MarketWatch

Schering-Plough profit triples, beats forecasts  Apr 20, 2006
...$78 million. Revenue from brain cancer drug Temodar grew 25 percent to $163 million, bolstered by greater sales-force support. The ... - Reuters

Schering-Plough 1st-Qtr Net Triples on Drug Sales (Update1)  Apr 20, 2006
...million. Sales of Temodar, a treatment for brain tumors, rose 25 percent to $163 million, and Nasonex grew 25 percent to $229 million. ... - Bloomberg

Cholesterol drugs boost Merck and Schering  Apr 20, 2006
...products including 26 per cent for Remicaid, for rheumatoid arthritis, 25 per cent on respiratory drug Nasonex, 25 per cent on cancer treatment Temodar and 16 ... - MSNBC

Drugmakers post 1st-quarter profit gains  Apr 20, 2006
...$2.55 billion. It also reported higher sales for the brain tumor treatment Temodar and hepatitis C drug Peg-Intron. Deutsche Bank ... - BusinessWeek

Schering-Plough Q1 Profit Soars On Strong Product Sales - Update  Apr 20, 2006
16% to $196 million. The company's brain cancer therapy Temodar saw sales ramp up 25% to $163 million. Sales of the drugmaker's ... - Trading Markets,

Earnings Roundup: First-quarter earnings triple at Schering  Apr 20, 2006
Schering-Plough's other hepatitis C drug, the pill Rebetol, rose 22 percent, to $78 million, and cancer drug Temodar grew 25 percent, to $163 million. ... - Newark Star Ledger,

NeoPharm: more promising survival data for cintredekin besudotox  Apr 25, 2006
As Schering-Plough's Temodar/Temodal (temozolomide) was previously used in recurrent GBM, since its recent approval in the first-line setting, there exists a ... - Pharmaceutical Business Review

EntreMed presents preclinical results for Panzem and ENMD-1198  Apr 27, 2006
In one preclinical study, daily oral administration of 2ME2 in combination with a maximally tolerated course of Temodar (temozolomide) resulted in 87% growth ... - Therapeutics Daily (subscription) (press release),

Google profits skyrocket; GM slows losses  Apr 21, 2006
...to $2.55 billion. It also reported higher sales for the brain tumor treatment Temodar and hepatitis C drug Peg-Intron. Bank of America ... - TheNewsTribune.com (subscription),

Schering-Plough quarterly earnings triple behind strong sales  Apr 20, 2006
...medications, said quarterly sales rose 7.7 percent, to $2.55 billion, as it also reported growth in sales of the brain tumor treatment Temodar and hepatitis C ... - Fort Worth Star Telegram,

Administration of valproic acid decreases oral clearance of temozolomide by about 5%. The clinical implication of this effect is not known.

Patients with Severe Hepatic or Renal Impairment

Caution should be exercised when TEMODAR Capsules are administered to patients with severe hepatic or renal impairment.